© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Sydney Jennings
Articles
FDA Approves AbbVie's Combination Antibiotic Emblaveo for Complicated Intra-Abdominal Infections
February 07, 2025
The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.
Nasal COVID-19 Vaccine Poised to Enter Phase 1 US Clinical Trial
February 07, 2025
The study will assess the safety and efficacy of a next-generation COVID-19 vaccine via nasal spray and inhalation.
US Dementia Cases to Double by 2060: Daily Dose
February 07, 2025
Your daily dose of the clinical news you may have missed.
FDA Approves New Wearable Treatment for Parkinson Disease
February 06, 2025
Onapgo is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in people with advanced Parkinson disease.
New Study Links Major Depressive Disorder to Specific Changes in Eating Preferences
February 06, 2025
People with MDD demonstrated a preference for carbohydrate-rich foods and reduced reward from fat- and protein-rich foods, according to new research.
FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose
February 06, 2025
Your daily dose of the clinical news you may have missed.
Investigators Identify Hemoglobin A1c/HDL-C as a Predictor of Stroke Risk in Older Adults
February 05, 2025
Elevated HbA1c/HDL-C ratios significantly increased stroke risk, even after adjusting for confounding factors, reported authors of a recent study.
Roche Receives FDA 510(k) Clearance for First US Blood Test Measuring Lp(a) in Molar Units
February 05, 2025
The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.
Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose
February 05, 2025
Your daily dose of the clinical news you may have missed.
MindMed Initiates Second Phase 3 Trial of Psychedelic MM120 for Generalized Anxiety Disorder
February 04, 2025
The first patient was dosed in the Panorama study assessing MM120 ODT, a form of LSD, for the treatment of GAD.